携带幽门螺杆菌中性粒细胞激活蛋白活减毒鼠伤寒沙门菌口服重组DNA疫苗株的构建

图1 重组质粒pBT-napA及pIRES-napA鉴定图谱. 1: 100 bp DNA Ladder marker; 2: PCR amplified product of HP-NAP; 3: Recombinant plasmid pBT-napA; 4: pBT-napA/Xho I + Mlu I; 5: Plasmid pIRES; 6: Recombinant vector pIRES-napA; 7: pIRES-napA/Xho I + Mlu I; 8: PCR amplified product of pIRES-napA; 9: Plasmid SL 7207/pIRES-napA extracted from ending-host SL 7207; 10: SL 7207/pIRES-napA/Xho I + Mlu I; 11: PCR amplified product of SL 7207/pIRES-napA; 12: DNA marker DL 2000 + 15 000.

图2 重组质粒pBT-napA及pIRES-napA构建示意图.

图3 幽门螺杆菌-napA核苷酸序列及其推导的氨基酸序列.

图4 HP-NAP抗原性分析(Welling法). A: H. pylori SS1 HP-NAP; B: 目的序列.